Production, characterization, and in vivo half-life extension of polymeric IgA molecules in mice.

Autor:	Lombana TN; a Department of Antibody Engineering, Genentech Inc., South San Francisco , CA , USA., Rajan S; b Department of Preclinical and Translational Pharmacokinetics, Genentech Inc., South San Francisco , CA , USA., Zorn JA; c Department of Structural Biology, Genentech Inc., South San Francisco , CA , USA., Mandikian D; b Department of Preclinical and Translational Pharmacokinetics, Genentech Inc., South San Francisco , CA , USA., Chen EC; d Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco , CA , USA., Estevez A; c Department of Structural Biology, Genentech Inc., South San Francisco , CA , USA., Yip V; b Department of Preclinical and Translational Pharmacokinetics, Genentech Inc., South San Francisco , CA , USA., Bravo DD; e Department of Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco , CA , USA., Phung W; f Department of Microchemistry, Proteomics and Lipidomics, Genentech Inc. , South San Francisco , CA , USA., Farahi F; a Department of Antibody Engineering, Genentech Inc., South San Francisco , CA , USA., Viajar S; a Department of Antibody Engineering, Genentech Inc., South San Francisco , CA , USA., Lee S; a Department of Antibody Engineering, Genentech Inc., South San Francisco , CA , USA., Gill A; a Department of Antibody Engineering, Genentech Inc., South San Francisco , CA , USA., Sandoval W; f Department of Microchemistry, Proteomics and Lipidomics, Genentech Inc. , South San Francisco , CA , USA., Wang J; e Department of Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco , CA , USA., Ciferri C; c Department of Structural Biology, Genentech Inc., South San Francisco , CA , USA., Boswell CA; b Department of Preclinical and Translational Pharmacokinetics, Genentech Inc., South San Francisco , CA , USA., Matsumoto ML; c Department of Structural Biology, Genentech Inc., South San Francisco , CA , USA., Spiess C; a Department of Antibody Engineering, Genentech Inc., South San Francisco , CA , USA.
Jazyk:	angličtina
Zdroj:	MAbs [MAbs] 2019 Aug/Sep; Vol. 11 (6), pp. 1122-1138. Date of Electronic Publication: 2019 Jun 09.
DOI:	10.1080/19420862.2019.1622940
Abstrakt:	IgA antibodies have broad potential as a novel therapeutic platform based on their superior receptor-mediated cytotoxic activity, potent neutralization of pathogens, and ability to transcytose across mucosal barriers via polymeric immunoglobulin receptor (pIgR)-mediated transport, compared to traditional IgG-based drugs. However, the transition of IgA into clinical development has been challenged by complex expression and characterization, as well as rapid serum clearance that is thought to be mediated by glycan receptor scavenging of recombinantly produced IgA monomer bearing incompletely sialylated N-linked glycans. Here, we present a comprehensive biochemical, biophysical, and structural characterization of recombinantly produced monomeric, dimeric and polymeric human IgA. We further explore two strategies to overcome the rapid serum clearance of polymeric IgA: removal of all N-linked glycosylation sites creating an aglycosylated polymeric IgA and engineering in FcRn binding with the generation of a polymeric IgG-IgA Fc fusion. While previous reports and the results presented in this study indicate that glycan-mediated clearance plays a major role for monomeric IgA, systemic clearance of polymeric IgA in mice is predominantly controlled by mechanisms other than glycan receptor clearance, such as pIgR-mediated transcytosis. The developed IgA platform now provides the potential to specifically target pIgR expressing tissues, while maintaining low systemic exposure.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu